Showing 15 posts of 80 posts found.


Amgen skin cancer drug gets European approval

October 23, 2015
Research and Development Amgen, Imlygic, melanoma, skin cancer

Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …

MSD logo

Merck and Incyte to initiate Keytruda, epacadostat combo trial

October 15, 2015
Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer

Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …


MSD’s Keytruda receives green light from NICE for NHS use

October 12, 2015
Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer

The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …

Advanced melanoma

Novartis and Merck skin cancer drugs move through pipeline

August 20, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib

Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …


EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

Astrazeneca image

AstraZeneca bags another FDA orphan status in cancer

April 17, 2015
Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib

The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …

MedImmune image

AstraZeneca signs immuno-oncology deal with UK firm

April 16, 2015
Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab

UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …

Keytruda image

Merck’s cancer drug sees first ever early access nod

March 11, 2015
Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab

Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …

Cancer image

Precision medicine: the future of cancer treatment?

March 2, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood

There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …

Zelboraf image

Roche submits melanoma drug to FDA

December 15, 2014
Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib

Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …

BMS image

BMS therapeutic cancer vaccine given swift FDA appraisal

September 29, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo

Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …

GSK melanoma drug sees quick NICE nod

September 18, 2014
Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer

NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …

Merck surprise winner in PD-1 race

September 5, 2014
Medical Communications, Research and Development, Sales and Marketing Cancer, Merck, melanoma, pd-1

Merck has become the first company to bring a new class of cancer drug to the US market after the …

Pfizer Xalkori

US rivals Pfizer and Merck team up for lung cancer

August 27, 2014
Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab

The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …

Latest content